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Abstract: Intestinal barrier function is suggested to decrease with aging and may be improved by
pectin intake. The aim of this study was to investigate the effects of four weeks pectin supplementation
on gastrointestinal barrier function in vivo and ex vivo in different age groups. In a randomized,
double-blind, placebo-controlled, parallel study, 52 healthy young adults (18–40 years) and 48 healthy
elderly (65–75 years) received 15 g/day pectin or placebo for four weeks. Pre- and post-intervention,
in vivo gastrointestinal permeability by a multisugar test, and defense capacity in mucosal samples
were assessed. Sigmoid biopsies were collected post-intervention from subgroups for Ussing chamber
experiments and gene transcription of barrier-related genes. Pectin intervention did not affect in vivo
gastroduodenal, small intestinal, colonic, and whole gut permeability in young adults nor in elderly
(p ≥ 0.130). Salivary and fecal sIgA and serum IgA were not significantly different between pectin
versus placebo in both age groups (p ≥ 0.128). In both young adults and elderly, no differences in
transepithelial electrical resistance and fluorescein flux (p ≥ 0.164) and relative expression of genes
analyzed (p ≥ 0.222) were found between pectin versus placebo. In conclusion, intestinal barrier
function was not affected by four weeks pectin supplementation neither in healthy young adults nor
in healthy elderly.
Keywords: aging; dietary fiber; intestinal permeability; tight junctions; defense; gastrointestinal;
tolerance
1. Introduction
An intact epithelial barrier is important for intestinal health and general well-being [1,2]. Epithelial
cells are sealed by a junctional complex, which permits selective entry of nutrients, ions, and water
while restricting permeation of bacteria and their products. An increased permeability can lead to
translation of luminal antigens and thereby to intestinal and systemic inflammation. Consequently,
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intestinal barrier dysfunction has been associated with a variety of intestinal and systemic diseases [2]
and with aging [3–5]. Interest in nutritional interventions to improve intestinal barrier function is
increasing. Functional foods, which can be applied in targeted nutrition strategies, are added foods
or ingredients that may provide health benefits beyond basic nutritional impact and/or reduce the
risk of disease [6]. Examples of functional foods are food items enriched with dietary fibers. Pectin is
a complex polysaccharide originating from cell walls of, for example, citrus peel, apple, and sugar
beet pulp [7,8] and is composed of galacturonic acid, of which the residues are substituted with
methyl esters at the C6-carboxyl group and rhamnogalacturonan [9]. In addition, sugar beet pectin as
compared to, for example, citrus and apple pectins, comprises acetylation of homogalacturonan. In the
upper gastrointestinal (GI) tract, pectin is resistant to digestion and hydrolysis. Because of the complex
structure, pectin serves as substrate for fermentation by the microbiota in both the proximal and distal
colon, resulting in the production of beneficial short-chain fatty acids (SCFAs) [8,10,11]. Pectin may
impact the intestinal epithelial barrier indirectly, by modulating the colonic microbial composition
and activity, and/or directly act on the epithelial cells [12,13]. Especially, the SCFA butyrate has been
shown to both protect and repair intestinal barrier function, possibly via beneficial effects on junctional
proteins and underlying signaling cascades [14]. Moreover, dietary fibers are suggested to reinforce
intestinal barrier function through modulating the enteric immune system. It has been shown that
prebiotics can be sensed by dendritic cells and in some cases selectively be transferred to the lamina
propria via specialized epithelial cells (i.e., microfold (M) cells), thus signaling to the gut-associated
lymphoid tissue [15]. Pectin-enhanced diets have been shown to improve intestinal barrier function,
as reflected by decreased small intestinal permeability in infants with persistent diarrhea [16] and rat
studies [17,18] compared with control diets, whereas data on colonic permeability and responses to a
potential stressor are not available. Furthermore, studies on the effects of pectin on mucosal defense
capacity in healthy adults and elderly are lacking.
Within the development of functional foods to target specific health concerns, it is important to
study the impact of nutrition in relevant subgroup(s) [19]. For this reason, we included two different
age groups: young adults and elderly. The purpose of this study was to investigate both the functional
and structural effects of pectin on GI barrier function in vivo and ex vivo in young adults and elderly.
The primary aim was to investigate the effects of four weeks pectin supplementation on segment-specific
intestinal permeability in vivo, stratified for age group. Secondly, we aimed to investigate the effects of
four weeks pectin supplementation on ex vivo stressed and unstressed intestinal barrier function, the
expression of intestinal barrier related genes and mucosal defense parameters, all stratified for age
group. We hypothesized that four weeks pectin supplementation improves intestinal barrier function
and mucosal defense capacity in healthy subjects, while we expect effects to be most pronounced in
the elderly.
2. Materials and Methods
The Medical Ethics Committee of the Maastricht University Medical Center+ approved this
study, which has been designed and performed in accordance with the Declaration of Helsinki (latest
amendment of 2013, Fortaleza, Brazil) and Dutch Regulations on Medical Research involving Human
Subjects (1998). The study was performed at the Maastricht University Medical Center+ from March
2015 until April 2016. The trial has been registered in the Clinical Trials register (NCT02376270).
All participants gave written informed consent before prior to participation.
2.1. Subjects
Healthy men and women with a body mass index (BMI) between 20–30 kg/m2 were recruited
from two age groups by advertising, including young adults between 18–40 years of age and elderly
between 65–75 years of age. Key exclusion criteria included the presence of GI symptoms, history of any
chronic disorder or major surgery which potentially limited participation or completion of the study,
abdominal surgery interfering with GI function, self-reported human immunodeficiency virus, average
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alcohol consumption of >20 alcoholic units per week, smoking, pregnancy, lactation, blood donation
90 days prior to the study, use of antibiotics, antifungal medication, probiotics or prebiotics 90 days
before the start of the study, history of side effects towards pro- or prebiotic supplements, and use of
nonsteroidal anti-inflammatory drugs. Use of other medication or dietary supplements was reviewed
by a medical doctor, who decided on in- or exclusion based on the medications or supplements used.
Included subjects using medication had to use a stable dose. Moreover, serum C-reactive protein
concentrations were determined to exclude inflammation and infections, and they were measured by
immunoturbidimetric assay using Cobas 6000 analyzer (Roche, Mannheim, Germany).
2.2. Study Design
This study was designed as a randomized, double-blind, placebo-controlled, parallel-group study.
Per age group, randomization was performed to assign participants to the placebo or the pectin
intervention arm. An independent person generated both lists, for the young adults and the elderly,
of random allocations using a computerized procedure. All study participants and investigators were
blinded to intervention allocations until analyses were completed. Participants in the pectin group
received 15 g/day of sugar beet derived pectin (GENU® BETA pectin, CP Kelco Germany GmbH,
Grossenbrode, Germany) for four weeks. Participants in the placebo group received 15 g/day of
maltodextrin (GLUCIDEX® IT 12, Roquette Frères, Lestrem, France) for four weeks. Fifteen grams
daily were given, as this is considered a prebiotic dosage in the higher physiological range with a
minimal risk of side effects [20,21]. Furthermore, four weeks is considered sufficient to strengthen the
barrier function by direct effects or changes in intestinal microbiota composition and activity [22,23].
Both pectin and placebo were supplemented as dry powders free from off-flavors and odors, and they
were packed in closed sachets of a single dose of 7.5 g. Subjects were asked to ingest the supplements
twice daily, before breakfast in the morning and before diner in the evening, dissolved in approximately
200 mL of tap water, and mixed with flavored syrup (Karvan Cévitam®, Koninklijke De Ruijter B.V.,
Zeist, The Netherlands). Time of consumption had to be recorded, and empty and remaining sachets
were returned to the investigator. At baseline and after four weeks pectin or placebo supplementation,
segment-specific gut permeability tests were performed, and bio samples were collected (Figure 1).
Fecal samples were collected at home, stored at −20 ◦C until arrival at the study site, and immediately
stored at –80 ◦C. After fasting overnight, venous blood and saliva samples were collected and stored at
–80 ◦C until further use. Additionally, the GI symptom rating scale (GSRS) was completed at baseline
and at weekly intervals to check for GI tolerance. Due to the invasive character, a flexible sigmoidoscopy
without bowel preparation was performed only at the end of each intervention and in subgroups of
the young adults and elderly. A standard flexible colonoscope was inserted, and 12 biopsy specimens
were taken from the sigmoid colon region with a jumbo biopsy forceps (Boston Scientific, Kerkrade,
The Netherlands). Seven samples were kept viable in pre-oxygenated Krebs–Ringer bicarbonate (KRB)
solution on melting ice and directly transported to the laboratory for Ussing chamber experiments.
Five tissue samples were snap-frozen in liquid nitrogen and stored at −80 ◦C for later analyses.
Figure 1. Timeline of the intervention period. Gut permeability test, feces collection, blood and saliva
sampling, gastrointestinal symptom rating scale, sigmoidoscopy procedure, and placebo or pectin
supplementation were completed at the days as indicated by arrows. Intake of supplements continued
until all measurements were finished.
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2.3. Gut Permeability Test
Segment-specific permeability of the GI tract was assessed by a multisugar test as validated by
van Wijck et al. [24,25]. One day prior to testing, as well as during the test, subjects were instructed
to refrain from excessive physical exercise and alcohol consumption. After fasting overnight, a mix
of water-soluble, nondegradable sugar probes were ingested, comprising 1 g sucrose (Van Gilse,
Dinteloord, The Netherlands), 1 g lactulose (Centrafarm Services, Etten-Leur, The Netherlands), 0.5 g
mannitol (Roquette, Lestrem, France), 1 g sucralose (Tate and Lyle Ingredients Americas, Decatur,
IL, USA), and 1 g erythritol (Now Foods, Bloomindale, IL, USA), dissolved in 200 mL tap water.
After ingestion, participants collected 24 h urine output in two separate fractions: 0–5 h and 5–24 h,
respectively. During the first 5 h of urine collection, participants were asked to refrain from any food or
drinks, except for water ad libitum. Thereafter, participants were allowed to eat and drink as preferred,
except for sucralose-containing foods. When urine was delivered to the researcher, volumes of urine
fractions were determined, and urine aliquots were frozen at −80 ◦C until analysis. Sugar probes were
analyzed by isocratic ion-exchange high-performance liquid chromatography with mass spectrometry
as described previously [24,25]. Gastroduodenal permeability was determined by sucrose excretion
in 0–5 h urine, whereas small intestinal permeability was measured by calculating the lactulose to
mannitol (L/M) ratio in 0–5 h urine. Sucralose to erythritol (S/E) ratios in 5–24 h and 0–24 h urine were
used as indicators for colonic and whole gut permeability, respectively.
2.4. Mucosal Defense Parameters
For total secretory immunoglobulin A (sIgA) determination, fecal samples were thawed, 1:5 diluted
with sodium chloride, incubated for 96 h, and measured by radial immunodiffusion using a commercial
test kit (Binding Site, Birmingham, United Kingdom). Immunoglobulin A (IgA) subclasses IgA1 and
IgA2 in serum and saliva samples were quantified by enzyme-linked immunosorbent assay. To this
end, high-binding 96-well plates (Greiner Bio one 655061, Monroe, NC, USA) were coated with goat
anti-human IgA-antibody preparation (Southern Biotech, 2050-01, Birmingham, United Kingdom),
which was diluted in phosphate-buffered saline (PBS) at a coating concentration of 1 µg/mL for serum
detection and 0.1 µg/mL for saliva detection, and were incubated overnight at 4 ◦C. The plates were
blocked with 5% fat-free milk powder in PBS at 150 µL/well for 1–2 h at room temperature (RT).
After washing three times with wash buffer (PBS + 0.05% Tween-20, Merck, Darmstadt, Germany),
a total of 100 µL IgA1 or IgA2 standards and test samples per well were applied on separate plates
for 1 h at 37 ◦C. Standard curves were set up on each plate, ranging from 200 to 0.2 ng/mL for both
IgA1 and IgA2. Serum samples were diluted in Universal Casein Diluent in PBS (PBSC) at 1:32,000
and 1:64,000 in IgA1 plates and at 1:400 and 1:800 in IgA2 plates. Saliva samples were diluted in
PBSC at 1:5000 and 1:10,000 on IgA1 plates and at 1:2000 and 1:10,000 on IgA2 plates. After washing
four times with wash buffer, secondary antibodies specific for human IgA1 (mouse anti-human IgA1
(at 1:5000 in PBSC) or mouse anti-human IgA2 (at 1:2000 in PBSC) (Southern Biotech, 9130-08 and
9140-08, respectively) were added at 100 µL/well and incubated for 1 h at RT. After washing four
times with wash buffer, 100 µL/well streptavidin-horseradish peroxidase (Southern Biotech, 7100-05),
diluted in PBSC at 1:5000, was added to the plates and incubated for 45 min at RT while covered with
aluminum foil. After washing six times with wash buffer, 100 µL/well 3,3’,5,5’-tetramethylbenzidine
(TMB) substrate solution (SDT, Baesweiler, Germany) was added to the plates and incubated for 15 min
at RT while covered with aluminum foil. The reaction was stopped by adding 2% HCL solution and
measured in a Filtermax microplate reader (Molecular Devices, San Jose, CA, USA) at 450 nm minus
620 nm as a reference value. After applying five-parameter logistic transformation, the data were
calculated according to best fit on the standard curve.
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2.5. Gastrointestinal Tolerance
The GSRS was completed at weekly intervals to check for GI tolerance. This instrument contained
15 items, and each item was graded by using a seven-point Likert-type scale where 1 represents absence
of troublesome symptoms and 7 represents very troublesome symptoms. The items were combined
into five subscales depicting reflux, abdominal pain, indigestion, diarrhea, and constipation [26].
2.6. Using Chamber Experiment
Six tissue samples from the sigmoid colon were used for ex vivo Ussing chamber experiments as
previously described by our group [27]. Three tissue samples were mildly stressed by adding 1 µg/mL
of the mast cell degranulator Compound 48/80 (Sigma-Aldrich, St. Louis, MO, USA) to the serosaL
compartment. Three non-exposed tissue samples served as unstressed controls. At t = 0, 1 mg/mL
fluorescein (376 g/mol, Sigma-Aldrich, St. Louis, MO, USA) was added to the serosal compartment
for determination of fluorescein flux to the luminal compartment. From all tissue samples, potential
difference (PD), transepithelial electrical resistance (TEER), and fluorescein concentrations were
determined at time point t = 0, 30, 60, 80, and 120 min. TEER and PD were used as quality criteria for
viability. Only samples with a baseline TEER above 20 Ω/cm2, or those with baseline TEER between
15–20 Ω/cm2 and PD below 0.5 mV, were included for analyses. TEER and fluorescein concentrations
are indicators of intestinal permeability.
2.7. Gene Transcription of Relevant Proteins
Transcription of junctional complex related genes, as well as defense- and immune-related genes
associated with barrier function or modulation thereof, were determined in colonic tissue samples.
Nucleic acid extraction and purification, RNA isolation, reverse transcription, and quantitative real-time
polymerase chain reaction (qRT-PCR) were performed as previously described [28]. Depending on the
gene of interest, cDNA was diluted to final concentrations of 20, 40, or 80 ng/µL (Table S1). Expressions
of target genes were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S
ribosomal RNA (18S RNA) as reference genes (Table S1).
2.8. Immunofluorescence Staining of TJP1 and Occludin
Sigmoid biopsy sections (10 µm) were used for immunofluorescent staining of TJP1 and occludin
as previously described by our group [29].
2.9. Statistical Analyses
The sample size calculation of the primary outcome (i.e., in vivo intestinal permeability) was based
on the difference in urinary lactulose/mannitol ratio between inulin-enriched pasta and control pasta in
young males as reported by Russo et al. [30]. A difference between treatments of 0.02, standard deviation
of 0.022, alpha of 0.025, and power of 0.80 were assumed. Thereby, a minimum of 24 completers per
intervention group in each age group were needed.
Intention to treat analyses were performed. Normality of the data was checked by histograms
and was summarized accordingly using the median and interquartile range (IQR; 25–75th IQR) or
means ± standard deviation for numerical variables as well as percentages for categorical variables.
Independent-sample t-tests were performed for numerical variables and chi-square tests for categorical
variables to test for differences between intervention groups (pectin versus placebo) in young adults
and in elderly.
Within each age group, differences between interventions were assessed by unstructured linear
mixed model analyses with intervention group (pectin and placebo), time (baseline and end) and
‘intervention group× time’ as fixed factors, and correction for baseline values. Differences in longitudinal
trends in TEER and luminal fluorescein between intervention groups were assessed by random intercept
linear mixed model analyses with intervention group (pectin and placebo), time (t = 0, 30, 60, 90, and
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120 min) and ‘intervention group × time’ as fixed factors, and correction for t = 0 values. All statistical
analyses were performed for young adults and elderly separately using IBM SPSS Statistics for
Windows (version 25.0, IBM Corporation, Armonk, NY, USA). A p-value ≤ 0.05 (two-sided) was
considered statistically significant. GI symptoms, Ussing chamber experiments, and gene transcription
p-values were corrected for multiple testing by the false discovery rate (FDR) of Benjamini–Hochberg.
3. Results
3.1. Study Subjects
After assessment of eligibility, 52 young adults and 48 elderly were enrolled in the study.
Three young adults dropped out, one because of overt noncompliance and two because of antibiotic
use (Figure 2). Baseline characteristics of the young adults and elderly, undergoing either pectin or
placebo intervention, are shown in Table 1.
Figure 2. Flow diagram of the study.
Table 1. Baseline characteristics of the total sample of young adults (n = 52) and elderly (n = 48),
undergoing either placebo or pectin intervention.
Parameter
Young Adults (n = 52) Elderly (n = 48)
Pectin (n = 25) Placebo (n = 27) p-Value Pectin (n = 24) Placebo (n = 24) p-Value
Age (years, mean ± SD) 23.4 ± 4.5 22.8 ± 4.1 0.613 69.5 ± 3.1 69.8 ± 2.4 0.723
Sex (% female) 68.0 48.1 0.148 37.5 50.0 0.383
BMI (kg/m2, mean ± SD) 23.2 ± 2.7 22.6 ± 2.7 0.444 25.5 ± 2.6 26.2 ± 2.8 0.334
Serum CRP (mg/L, mean ± SD) 1.7 ± 2.5 1.0 ± 1.2 0.161 1.1 ± 1.3 1.8 ± 2.1 0.203
Medication (%)
N.A. N.A. N.A.
PPI 12.5 12.5 1.000
Statins 4.2 4.2 1.000
Antihypertensives 12.5 8.3 0.637
Alcohol consumption
(units/week, mean ± SD) 3.5 ± 3.2 5.3 ± 5.4 0.165 8.4 ± 6.9 9.3 ± 7.1 0.667
BMI: body mass index, CRP: C-reactive protein, N.A: not applicable, and PPI: proton-pump inhibitors. Age, BMI,
CRP, and alcohol consumption were compared between intervention groups with the use of an independent samples
t-test. Sex and medication were compared between intervention groups with the use of a Pearson’s chi-square test.
Moreover, a subgroup of 22 young adults and 22 elderly underwent a sigmoidoscopy after four
weeks pectin or placebo intervention (Figure 2), of which baseline characteristics are shown in Table S2.
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3.2. Intestinal Permeability In Vivo
Gastroduodenal and small intestinal permeability, as assessed by the 0–5 h urinary sucrose
excretion and 0–5 h urinary L/M ratio, respectively (Figure 3), did not differ significantly between
four weeks pectin and placebo supplementation in the young adults nor in the elderly (all p ≥ 0.861).
The 5–24 h urinary S/E ratio and 0–24 h urinary S/E ratio (Figure 4), as measures of colonic and whole gut
permeability, were not significantly different between four weeks pectin vs. placebo supplementation
in both young adults and elderly (all p ≥ 0.130).
Figure 3. Gastroduodenal and small intestinal permeability in vivo at baseline and after four weeks
of placebo (triangles) and pectin (circles) intervention in young adults and elderly. (A) 0–5 h urinary
sucrose excretion (µmol) in young adults. (B) 0–5 h urinary sucrose excretion (µmol) in elderly. (C) 0–5 h
urinary lactulose/mannitol ratio in young adults. (D) 0–5 h urinary lactulose/rhamnose ratio in elderly.
Values are presented in scatter plots with median line and IQR (25–75th interquartile range). Sample
size differences between baseline and end are due to drop-outs. Within age groups, urinary sugar
excretions and ratios were compared between intervention groups with an unstructured linear mixed
model and correction for baseline values.
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Figure 4. Colonic and whole gut permeability in vivo at baseline and after four weeks of placebo
(triangles) and pectin (circles) intervention in young adults and elderly. (A) 5–24 h urinary sucralose/
erythritol ratio in young adults. (B) 5–24 h urinary sucralose/erythritol ratio in elderly. (C) 0–24 h
urinary sucralose/erythritol ratio in young adults. (D) 0–24 h urinary sucralose/erythritol ratio in
elderly. Values are presented in scatter plots with median line and IQR (25–75th interquartile range).
Sample size differences between baseline and end are due to drop-outs. Within age groups, urinary
sugar ratios were compared between intervention groups with unstructured linear mixed models and
correction for baseline values.
3.3. Mucosal Defense Parameters
No significant changes in salivary sIgA1 and sIgA2, serum IgA1 and IgA2, and fecal sIgA were
observed between pectin or placebo intervention, neither in young adults nor in elderly (all p ≥ 0.128)
(Figure S1).
3.4. Gastrointestinal Tolerance
GI tolerance was assessed weekly by completing the GSRS questionnaire. After FDR correction
for multiple testing, GI symptom scores were not significantly different between pectin and placebo
supplementation in young adults nor in elderly (all p ≥ 0.054) (Figures S2 and S3, respectively).
In young adults, however, pectin intervention induced significantly higher diarrhea scores (p = 0.020)
compared with placebo at week two only (Figure S2).
3.5. Intestinal Permeability Ex Vivo
Using chamber experiments were done to determine ex vivo TEER and luminal fluorescein
concentration as indicators of paracellular permeability in unstressed and stressed conditions. After FDR
correction for multiple time points, TEER in unstressed and stressed biopsies did not significantly
differ between four weeks pectin versus placebo supplementation in elderly nor in young adults
(all p ≥ 0.226) (Figure 5). In both young adults and elderly, luminal fluorescein concentrations in
unstressed and stressed biopsies did not differ significantly between four weeks pectin vs. placebo
supplementation (all p ≥ 0.164) (Figure 6).
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Figure 5. Intestinal permeability ex vivo after four weeks of pectin (fixed lines) and placebo (dashed
lines) intervention in young adults and elderly. Analyses were conducted by mounting fresh sigmoid
biopsies in an Ussing chamber system and assessing transepithelial electrical resistance (TEER) at
t = 0, 30, 60, 90, and 120 min. (A) TEER in young adults in unstressed biopsies. (B) TEER in elderly in
unstressed biopsies. (C) TEER in young adults in biopsies stressed by 1 µg/mL Compound 48/80 at t = 0.
(D) TEER in elderly in biopsies stressed by 1 µg/mL Compound 48/80 at t = 0. Means and standard
deviations are shown. Sample sizes varied because baseline values of some sigmoid biopsies did not
meet quality criteria for viability. Within age groups, TEER and luminal fluorescein were compared
between intervention groups with random intercept linear mixed models and correction for baseline
values. p-values per time point were corrected for multiple testing by calculating the false discovery
rate (FDR) of Benjamini–Hochberg.
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Figure 6. Intestinal permeability ex vivo after four weeks of pectin (fixed lines) and placebo (dashed
lines) intervention in young adults and elderly. Analyses were conducted by mounting fresh sigmoid
biopsies in an Ussing chamber system and assessing luminal fluorescein concentration at t = 0, 30, 60, 90,
and 120 min. (A) Luminal fluorescein concentration in young adults in unstressed biopsies. (B) Luminal
fluorescein concentration in elderly in unstressed biopsies. (C) Luminal fluorescein concentration
in young adults in biopsies stressed by 1 µg/mL Compound 48/80 at t = 0. (D) Luminal fluorescein
concentration in elderly in biopsies stressed by 1 µg/mL Compound 48/80 at t = 0. Means and standard
deviations are shown. Sample sizes varied because baseline values of some sigmoid biopsies did not
meet quality criteria for viability. Within age groups, luminal fluorescein concentrations were compared
between intervention groups with random intercept linear mixed models. p-values per time point were
corrected for multiple testing by calculating the false discovery rate (FDR) of Benjamini–Hochberg.
3.6. Gene Transcription of Barrier-Related Genes
Mean Cq values of both GAPDH and 18S RNA did not differ between pectin and placebo
intervention. GAPDH normalized relative expression of junctional complexes (e.g., tight junctions
and adheren junctions) as well as defense- and immune-related (e.g., human defensins, cytokines, and
toll-like receptor) genes in sigmoid biopsies of young adults and elderly after four weeks pectin or
placebo intervention are shown in Table 2. After FDR correction for multiple testing, in both young
adults and elderly, no significant differences were found between pectin vs. placebo intervention
(all p ≥ 0.222) in the relative expression of all genes analyzed. Moreover, analyses on 18S RNA
normalized gene expressions resulted in the same conclusions.
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Table 2. Relative expression of junctional complexes (e.g., tight junction related and adheren junctions) and defense- and immune-related (e.g., human defensins,
cytokines, and toll-like receptor) genes in sigmoid biopsies of young adults and elderly after four weeks pectin or placebo intervention.
Cluster Gene Name
Young Adults Elderly
Pectin Placebo p-Value Benjamini–Hochbergp-Value Pectin Placebo p-Value
Benjamini–Hochberg
p-Value
Junctional complex related genes
TJP1 (ZO-1) 1.15 ± 0.03 1.13 ± 0.03 0.313 0.417 1.15 ± 0.02 1.13 ± 0.02 0.195 0.260
OCLN 1.19 ± 0.02 1.18 ± 0.02 0.128 0.417 1.20 ± 0.01 1.19 ± 0.02 0.184 0.260
CLDN2 1.34 ± 0.07 1.36 ± 0.03 0.527 0.602 1.36 ± 0.05 1.32 ± 0.07 0.250 0.286
CLDN3 1.17 ± 0.02 1.16 ± 0.02 0.245 0.417 1.18 ± 0.03 1.16 ± 0.02 0.079 0.222
CLDN4 1.11 ± 0.03 1.10 ± 0.02 0.311 0.417 1.12 ± 0.02 1.10 ± 0.02 0.111 0.222
MLCK 1.15 ± 0.02 1.15 ± 0.03 0.982 0.982 1.16 ± 0.02 1.14 ± 0.03 0.109 0.222
CDH1 1.17 ± 0.02 1.15 ± 0.01 0.072 0.417 1.17 ± 0.03 1.17 ± 0.02 0.852 0.852
CTNNB1 1.13 ± 0.01 1.12 ± 0.01 0.236 0.417 1.15 ± 0.02 1.12 ± 0.02 0.029 0.222
Defense and immune related genes
CAMP 1.29 ± 0.05 1.30 ± 0.05 0.630 0.770 1.32 ± 0.06 1.28 ± 0.06 0.179 0.405
DEFB1 1.17 ± 0.05 1.15 ± 0.03 0.468 0.735 1.18 ± 0.05 1.16 ± 0.03 0.184 0.405
MUC2 1.02 ± 0.03 1.01 ± 0.03 0.429 0.735 1.01 ± 0.03 1.01 ± 0.02 0.832 0.915
TFF3 0.99 ± 0.03 0.98 ± 0.04 0.432 0.735 0.98 ± 0.05 0.98 ± 0.04 0.832 0.915
IL1B 1.32 ± 0.05 1.35 ± 0.05 0.217 0.597 1.33 ± 0.04 1.31 ± 0.06 0.232 0.405
IL10 1.25 ± 0.07 1.25 ± 0.03 0.856 0.856 1.27 ± 0.05 1.23 ± 0.06 0.141 0.405
TNF 1.31 ± 0.05 1.35 ± 0.06 0.151 0.554 1.35 ± 0.04 1.35 ± 0.04 0.937 0.937
TLR1 1.15 ± 0.05 1.18 ± 0.04 0.144 0.554 1.16 ± 0.05 1.13 ± 0.04 0.153 0.405
TLR2 1.25 ± 0.06 1.26 ± 0.05 0.818 0.856 1.26 ± 0.06 1.23 ±.0.06 0.258 0.405
TLR4 1.19 ± 0.03 1.21 ± 0.03 0.056 0.554 1.21 ± 0.03 1.19 ± 0.03 0.042 0.405
TLR6 1.12 ± 0.06 1.29 ± 0.04 0.622 0.770 1.30 ± 0.07 1.27 ± 0.06 0.358 0.492
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as reference gene in this table since analyses on 18S RNA normalized gene expressions resulted in the same conclusions.
Values are presented as mean ± SD. For a limited number of genes, sample sizes may differ due to technical reasons. Within age groups, genes were compared between intervention groups
by independent-sample t-tests. p-values were corrected for multiple testing by calculating the false discovery rate of Benjamini–Hochberg per cluster. TJP1 (ZO-1): Tight junction protein 1
(i.e., Zona Occludens-1), OCLN: Occludin, CLDN: Claudin, MLCK: Myosin light chain kinase, CDH1: Cadherin 1, CTNNB1: Catenin beta 1, CAMP: Cathelicidin antimicrobial peptide,
DEFB1: Defensin beta 1, MUC2: Mucin 2, TFF3: Trefoil factor 3, IL: Interleukin, TNF: Tumor necrosis factor, and TLR: Toll-like receptor.
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3.7. Immunofluorescence Staining of TJP1 and Occludin
Visual inspection of representative immunofluorescence staining of TJP1 (Figure S4) and occludin
(Figure S5) in sigmoid biopsy sections showed no apparent differences between four weeks pectin
versus placebo supplementation in young adults nor in elderly. These observations are in line with
quantitative analyses of TJP1 and occludin gene transcription levels as reported in Table 2 as well as
with the functional analyses performed.
4. Discussion
In the current study, the impact of pectin on the functional and structural GI barrier in young
adults and elderly has been investigated in vivo and ex vivo. We showed that GI segment-specific
permeability, intestinal permeability ex vivo, expression of barrier-related genes, and parameters of
mucosal defense were not significantly improved by four weeks pectin supplementation neither in
healthy young adults nor in healthy elderly.
The present study was designed based on the previously described features of pectin intake.
It may strengthen the highly dynamic epithelial barrier directly by interacting with tight junction
proteins and indirectly via modulating the colonic microbial composition and activity, which is known
to affect intestinal homeostasis and barrier function. An intervention period of four weeks should
be adequate to both directly and indirectly modulate intestinal barrier function. Moreover, sugar
beet pectin was chosen because of the complex structure, which causes it to be fermented in both
the proximal and distal colon. Saccharolytic fermentation (i.e., fermentation of dietary fibers) may
inhibit fermentation of proteins in the distal colon due to substrate competition, thereby lowering the
production of mostly toxic compounds that result from proteolytic fermentation. The only previous
human study on pectin and intestinal permeability in vivo showed that one-week supplementation
with pectin (4 mg/kg body weight) improved small intestinal permeability (i.e., decreased 0–5 h urinary
L/M ratio) in infants with persistent diarrhea [16]. In our study, we found no significant effects of four
weeks pectin intake on small intestinal permeability, as determined by the 0–5 h urinary L/M ratio,
in healthy adults and healthy elderly. Because the type and dosage of pectin, intervention duration, and
target populations of both human studies differed, adequate comparison of these studies is difficult.
We also showed that gastroduodenal, colonic, and whole gut permeability, as determined by
the multisugar test, were not significantly affected by four weeks pectin supplementation. This may
be due to the well-functioning intestinal barrier at baseline in both the healthy young adults and
the elderly, although the intestinal epithelium is often exposed to stressors such as alcohol, high-fat
diet, medication use, psychological and psychosocial stress, etc. In the current study, subjects were
instructed to maintain their habitual diet. As we did not actually monitor food intake over the study
period, we cannot exclude that the intake of 15 g/day pectin or placebo may have impacted food intake.
Furthermore, it should be noted that the inter-individual variations were rather high, although this
was in accordance with previous observations [31]. This stresses the importance of assessments within
subjects, as was done in the current study, with measurements of the intestinal barrier before and after
the intervention period. As other dietary fibers (i.e., galacto-oligosaccharides) have been found to
improve colonic permeability in obese subjects [32], based on our results, we cannot exclude potential
impact of pectin on intestinal barrier function in more susceptible (sub)groups of adults or elderly.
To further examine the effect of pectin in stressed conditions, sigmoid biopsies were collected
at the end of each intervention in subgroups of the young adults and the elderly. Mucosal tissue
samples were used to determine intestinal permeability ex vivo in Ussing chamber experiments.
We used Compound 48/80 to induce a mild stress as reflected by an increase in luminal fluorescein
concentrations. Though, tissue TEER and mucosal fluorescein permeation were not affected by the
four weeks pectin versus placebo supplementation in the unstressed nor in the stressed condition.
Ganda Mall et al. [33] exposed sigmoid biopsies of elderly with GI symptoms and of healthy adults
with dietary fibers (i.e., yeast-derived beta-glucan and wheat-derived arabinoxylan) before adding
Compound 48/80. Especially in elderly with GI symptoms, beta-glucan was found to attenuate the
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hyperpermeability induced by Compound 48/80 as reflected by both higher TEER and lower mucosal
to serosal fluorescein concentrations. Differences with the current study may be explained by the more
vulnerable elderly population (i.e., with GI symptoms) and exposure to beta-glucan in vitro rather
than in vivo.
Relative expression levels of junctional complex, defense, and immune related genes in sigmoid
tissue samples also showed no significant differences between the sugar beet derived pectin and
placebo supplementation in any of the age groups after FDR correction. This was further supported
by immunofluorescence staining of TJP1 and occludin in representative sigmoid biopsy sections.
Interestingly, in rats which were selected by their response to a high-fat diet by gaining weight,
subsequent high-fat diet supplemented with apple-derived pectin versus normal high-fat diet resulted
in lower interleukin (IL)-6, tumor necrosis factor-α and TLR4, and higher IL-10 and claudin-1 mRNA
levels in ileal tissue, suggestive of an anti-inflammatory activity of this pectin [18]. However, possible
disturbances in intestinal barrier function induced by the high-fat diet, differences in pectin source,
and no corrections for multiple testing may explain, at least in part, different effects of the rat study
when compared to the current human intervention study. Furthermore, in a mice model of acute
pancreatitis, low-methoxyl pectin was found to upregulate occludin, TJP1, and defensin beta 1 as
well as downregulate tumor necrosis factor-α, IL-β, and IL-6 relative mRNA levels in ileal and
colonic tissue, pointing towards restoration of acute pancreatitis-associated disruption of the intestinal
barrier [34]. This is not in line with our observations, probably caused by the difference between
acute pancreatitis-induced animals versus healthy human participants and variation in degrees
of methylation.
The effects of four weeks pectin supplementation on mucosal defense capacity was further studied
by assessing salivary sIgA1 and sIgA2, fecal sIgA, and serum IgA1 and IgA2, demonstrating no
significant effect of the pectin intervention in any of the age groups. Production of sIgA in the human
intestine in absolute quantities exceeds that of all other antibody classes together [35], and IgA can
be seen as a key antibody class for the first line of defense in mucous membranes. Human studies
investigating the effects of other dietary fibers on human mucosal defense, as assessed by salivary and
fecal sIgA in vivo, have been performed previously [36–39]. However, to our knowledge, this is the
first human study investigating the effects of sugar beet pectin supplementation on IgA levels. In a
rat study comparing pectin (unspecified origin) versus cellulose-supplemented diets, higher serum
IgA concentrations in pectin-supplemented rats were found [40], although sIgA was not determined.
Conflicting results between rat and human studies can be caused by differences in pectin source or
normal physiological processing of the IgA molecule, and the fact that only humans have two isotypes
of IgA that are differentially regulated and distributed.
GI symptoms were determined throughout the four weeks pectin supplementation period to
monitor GI tolerance. Although pectin, in comparison to placebo, did not alter any GI symptom score
in the elderly, pectin caused an increase in the diarrhea score after two weeks pectin intake by young
adults. After four weeks of pectin intervention, diarrhea decreased and was no longer significantly
different compared to placebo, illustrating habituation to 15 g/day of pectin supplementation in young
adults. This habituation period is in line with previous findings on dietary fibers and the occurrence
of gastrointestinal symptoms [41,42], and it may, in the case of pectin supplementation, be due to
increased microbial fermentation and/or increased viscosity in the colonic lumen.
5. Conclusions
In conclusion, by using a combined in vivo and ex vivo approach, we consistently showed that
intestinal barrier function was not affected by four weeks sugar beet pectin supplementation neither in
healthy young adults nor in healthy elderly. As there are clear leads in literature that dietary fibers may
improve the intestinal barrier, but clinical data are still limited, further human intervention studies
are needed to explore potential effects of pectin and other dietary fibers in patients with an impaired
intestinal barrier function.
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Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/7/1554/s1,
Figure S1: Mucosal defense parameters at baseline and after four weeks of pectin (circles) or placebo (triangles)
intervention in young adults and elderly. A: Salivary sIgA1 (g/mL) in young adults. B: Salivary sIgA1 (g/mL) in
elderly. C: Salivary sIgA2 (g/mL) in young adults. D: Salivary sIgA2 (g/mL) in elderly. E: Serum IgA1 (g/mL) in
young adults. F: Serum IgA1 (g/mL) in elderly. G: Serum IgA2 (g/mL) in young adults. H: Serum IgA2 (g/mL)
in elderly. I: Fecal sIgA (g/L) in young adults. J: Fecal sIgA (g/L) in elderly. Values are presented in scatter
plots with median line and IQR (25–75th interquartile range). Sample sizes vary due to drop-outs and technical
reasons. Within age groups, mucosal defense parameters were compared between intervention groups with
unstructured linear mixed models and correction for baseline values. IgA, Immunoglobulin A; sIgA, secretory
Immunoglobulin A, Figure S2: Gastrointestinal symptoms at baseline and every week of pectin (fixed lines) and
placebo (dashed lines) intervention in young adults. A: Abdominal pain scores. B: Constipation scores. C: Diarrhea
scores. D: Indigestion scores. E: Reflux scores. Means and standard deviations are shown. Missing values at
specific weeks were due to drop-outs. Gastrointestinal symptom scores were compared between intervention
groups with random intercept linear mixed models and correction for baseline values. p-values per time point
were corrected for multiple testing by calculating the false-discovery-rate (FDR) of Benjamini-Hochberg, Figure
S3: Gastrointestinal symptoms at baseline and every week of pectin (fixed lines) and placebo (dashed lines)
intervention in elderly. A: Abdominal pain scores. B: Constipation scores. C: Diarrhea scores. D: Indigestion
scores. E: Reflux scores. Means and standard deviations are shown. Gastrointestinal symptom scores were
compared between intervention groups with random intercept linear mixed models and correction for baseline
values. p-values per time point were corrected for multiple testing by calculating the false-discovery-rate (FDR) of
Benjamini-Hochberg, Figure S4: Representative images of tight junction protein TJP1 (green) immunofluorescence
staining in sigmoid biopsy sections of a healthy young adult and healthy elderly after four weeks pectin or placebo
intervention. Scale bar represents 100 µm. Blue counterstaining (DAPI) shows nuclei. TJP1: Tight junction
protein 1, Figure S5: Representative images of tight junction protein occludin (red) immunofluorescence staining
in sigmoid biopsy sections of a healthy young adult and healthy elderly after four weeks pectin or placebo
intervention. Scale bar represents 100 µm. Blue counterstaining (DAPI) shows nuclei, Table S1: Forward and
reverse primer sequences and final cDNA concentrations of all target genes, as determined in sigmoid biopsies,
Table S2: Baseline characteristics of the subgroups of young adults (n = 22) and elderly (n = 22), undergoing
sigmoidoscopy after the pectin or placebo intervention.
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